» Authors » David A Hildeman

David A Hildeman

Explore the profile of David A Hildeman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 89
Citations 4103
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Moreno-Fernandez M, Sharma V, Stankiewicz T, Oates J, Doll J, Damen M, et al.
Nutr Diabetes . 2021 Jun; 11(1):15. PMID: 34099626
Background: Understanding gender-associated bias in aging and obesity-driven metabolic derangements has been hindered by the inability to model severe obesity in female mice. Methods: Here, using chow- or high fat...
22.
Kirk A, Adams A, Durrbach A, Ford M, Hildeman D, Larsen C, et al.
Am J Transplant . 2020 Oct; 21(5):1691-1698. PMID: 33128812
Kidney transplant recipients administered belatacept-based maintenance immunosuppression present with a more favorable metabolic profile, reduced incidence of de novo donor-specific antibodies (DSAs), and improved renal function and long-term patient/graft survival...
23.
Almanan M, Raynor J, Ogunsulire I, Malyshkina A, Mukherjee S, Hummel S, et al.
Sci Adv . 2020 Aug; 6(31):eabb0806. PMID: 32832688
Aging results in profound immune dysfunction, resulting in the decline of vaccine responsiveness previously attributed to irreversible defects in the immune system. In addition to increased interleukin-6 (IL-6), we found...
24.
Raynor J, Lin A, Hummel S, Lampe K, Jordan M, Hoebe K, et al.
Front Immunol . 2020 Mar; 11:197. PMID: 32153566
Increasing evidence points to a key role for NK cells in controlling adaptive immune responses. In studies examining the role of CD1d on CD4+ T cell responses, we found that...
25.
Castro-Rojas C, Alloway R, Woodle E, Hildeman D
Curr Transplant Rep . 2019 Oct; 6(1):60-68. PMID: 31595214
Purpose Of Review: The goal of this review is to discuss new approaches to avoid CNI/CCS toxicities with a focus on new biologics and new methods to understand transplant rejection...
26.
Li K, Ladle B, Kurtulus S, Sholl A, Shanmuganad S, Hildeman D
Cell Death Differ . 2019 Sep; 27(4):1214-1224. PMID: 31558776
Most effector CD8 T cells die, while some persist and become either "effector" (T) or "central" (T) memory T cells. Paradoxically, effector CD8 T cells with greater memory potential have...
27.
Tremblay S, Driscoll J, Rike-Shields A, Hildeman D, Alloway R, Girnita A, et al.
Am J Transplant . 2019 Sep; 20(2):411-421. PMID: 31550069
Proteasome inhibitor-based strategies hold promise in transplant but have yielded varying results. Carfilzomib, a second-generation proteasome inhibitor, may possess advantages over bortezomib, the first-generation proteasome inhibitors. The purpose of this...
28.
Castro-Rojas C, Godarova A, Shi T, Hummel S, Shields A, Tremblay S, et al.
Transplantation . 2019 Aug; 104(5):1058-1069. PMID: 31415033
Background: Renal allograft rejection is more frequent under belatacept-based, compared with tacrolimus-based, immunosuppression. We studied kidney transplant recipients experiencing rejection under belatacept-based early corticosteroid withdrawal following T-cell-depleting induction in a...
29.
Arazi A, Rao D, Berthier C, Davidson A, Liu Y, Hoover P, et al.
Nat Immunol . 2019 Aug; 20(10):1404. PMID: 31409923
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
30.
Arazi A, Rao D, Berthier C, Davidson A, Liu Y, Hoover P, et al.
Nat Immunol . 2019 Jun; 20(7):902-914. PMID: 31209404
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients...